Innovative Product Launches The recent launch of BÜHLMANN fCAL turbo and fPELA turbo assays demonstrates the company's commitment to expanding its diagnostic portfolio with high-throughput, automated solutions, presenting opportunities to target laboratories seeking efficient, advanced testing options.

Strategic Industry Partnerships Collaboration with QuidelOrtho to integrate BÜHLMANN’s assays into the VITROS Systems suggests a strong foothold in the automated testing market, opening avenues for sales discussions around similar OEM or integration partnerships with other diagnostic platform providers.

Market Expansion Activities Participation in key industry events like the Peripheral Nerve Society Annual Meeting highlights opportunities to engage with clinical research institutions and specialty labs focused on inflammatory and nerve-related diagnostics, where BÜHLMANN’s innovative tests can meet emerging clinical needs.

Leadership and Innovation Focus The appointment of new executives and ongoing R&D collaborations, such as peptide-based calprotectin ligands development, position BÜHLMANN as a forward-thinking company, ideal for targeting customers interested in cutting-edge diagnostic solutions and scientific collaborations.

Global Presence and Local Focus With teams across Switzerland, Europe, and the Americas, BÜHLMANN offers a global distribution network and localized sales opportunities, particularly for expanding its presence in markets like the USA, Brazil, and Europe where specialized diagnostics are in high demand.